|
|
News Breaks
|
October 13, 2009
|
| 07:35 EDT |  | DYAX |
| theflyonthewall.com: | Dyax announces drug candidates' new developments | | Dyax Corp. announced new developments involving drug candidates identified using the Company’s proprietary phage display technology as a result of two deals recently announced by sanofi-aventis. Sanofi-aventis announced plans to acquire Fovea Pharmaceuticals, Dyax’s partner for DX-88 in ophthalmic indications in the European Union. DX-88, one of Fovea’s three pipeline products, is in Phase 1 development for the treatment of retinal vein occlusion induced macular edema. Under the terms of the Dyax-Fovea partnership agreement, Fovea has exclusive rights to the intravitreal formulation of DX-88 in ophthalmic indications in the EU. Fovea will fully fund development for the RVO induced macular edema program for approval in worldwide markets. Dyax retained rights for ophthalmic indications for all territories outside the EU. :theflyonthewall.com |
|
|
News For DYAX From The Last 14 Days Check below for free stories on DYAX the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
